Hepion Pharma CEO Kaouthar Lbiati resigns; separation agreement provides $225K payment

Hepion Pharmaceuticals, Inc.

Separation agreement pays Dr. Lbiati $225,000, $30,625 pro-rata bonus, and 6 months COBRA reimbursement.
Lbiati resigned as CEO on March 16, 2026, and as director on April 13, 2026.
Gary Stetz serves as Interim CEO effective from the separation date.
Separation includes a general release and confidentiality covenant.

item 1.01item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.